​
​

Verastem (VSTM) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Verastem Revenue Highlights

0

Latest Revenue (Q)

$10.00M

Main Segment (Y)

Sale of COPIKTRA license and related assets

Verastem Revenue by Period

Verastem Revenue by Year

DateRevenueChange
2023-12-31--100.00%
2022-12-31-26.45%
2021-12-31--97.68%
2020-12-31-407.08%
2019-12-31--34.67%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31--

Verastem generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Verastem Revenue by Quarter

DateRevenueChange
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31-100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31--100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30--100.00%
2022-03-31-376.33%
2021-12-31-27150.00%
2021-09-30--99.60%
2021-06-30--50.30%
2021-03-31-98.81%
2020-12-31--99.36%
2020-09-30-1726.03%
2020-06-30--14.81%
2020-03-31-39.82%
2019-12-31--59.96%
2019-09-30-188.01%
2019-06-30-87.67%
2019-03-31-38.10%
2018-12-31--92.20%
2018-09-30-55.08%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2011-03-31--

Verastem generated $10.00M in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Verastem Revenue Breakdown

Verastem Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19Dec 18
Sale of COPIKTRA license and related assets-----
Copiktra license and related assets-----
Government rebates and other incentives-----
Trade discounts and allowances-----
Returns-----
Product Revenue And Allowances Returns-----
Product Revenue Reserves And Allowances Trade Discounts And Allowances-----
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees-----
Product Revenue Reserves And Allowances Government Rebates And Other Incentives-----

Verastem's latest annual revenue breakdown by segment (product or service), as of Dec 22: Sale of COPIKTRA license and related assets (100.00%).

Quarterly Revenue by Product

Product/ServiceMar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18
Sale of COPIKTRA license and related assets---------------
Copiktra license and related assets---------------
Transition Services Revenue---------------
Copiktra License And Related Assets---------------
Product Revenue Reserves And Allowances Government Rebates And Other Incentives---------------
Product Revenue And Allowances Returns---------------
Product Revenue Reserves And Allowances Trade Discounts And Allowances---------------
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees---------------

Verastem's latest quarterly revenue breakdown by segment (product or service), as of Mar 22: Sale of COPIKTRA license and related assets (100.00%).

Verastem Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18
Sale of COPIKTRA license and related assets---------------
Copiktra license and related assets---------------
Transition Services Revenue---------------
Copiktra License And Related Assets---------------
Product Revenue And Allowances Returns---------------
Product Revenue Reserves And Allowances Government Rebates And Other Incentives---------------
Product Revenue Reserves And Allowances Trade Discounts And Allowances---------------
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees---------------

Verastem's latest quarterly revenue breakdown by geography, as of Mar 22: Sale of COPIKTRA license and related assets (100.00%).

Verastem Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
KPTIKaryopharm Therapeutics--
TRVNTrevena--
INFIInfinity Pharmaceuticals--
ACRXTalphera--
VSTMVerastem--
VKTXViking Therapeutics--

VSTM Revenue FAQ

What is Verastem’s yearly revenue?

Verastem's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $2.6M, representing an increase of 26.45% compared to 2021. VSTM's yearly revenue for 2021 was $2.05M, representing a decrease of -97.68% compared to 2020.

What is Verastem’s quarterly revenue?

Verastem's quarterly revenue for Q2 2024 was $10M, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). VSTM's quarterly revenue for Q4 2023 was $114K, a 100.00% increase from the previous quarter (Q3 2023), and a -95.61% decrease year-over-year (Q4 2022).

What is Verastem’s revenue growth rate?

Verastem's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.

What are Verastem’s revenue streams?

Verastem's revenue streams in c 22 are Sale of COPIKTRA license and related assets

What is Verastem’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Verastem was Sale of COPIKTRA license and related assets. This segment made a revenue of $2.6M, representing 100.00% of the company's total revenue.